Citigroup’s Impact BioMedical IBO Stock Holding History

Citigroup’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11	Buy	+2	New	+$12	﹤0.01%	5796
2026 Q2	–	Sell	-28	Closed	-$209	–	6351
2026 Q1	$212	Buy	+28	New	+$177	﹤0.01%	5575
2025 Q4	–	Sell	-269	Closed	-$1.8K	–	6004
2025 Q3	$2.26K	Sell	269 -427	-61%	-$3.4K	﹤0.01%	5455
2025 Q2	$5.68K	Buy	+696	New	+$4.93K	﹤0.01%	5262

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Global Trust Asset Management West Palm Beach, Florida $321M AUM 60.77% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Burk Holdings Tulsa, Oklahoma $289M AUM 16.51% 1-Year Est. Return

Citigroup's IBO Position: Q3 2026 in Review

Citigroup opened a new position in Impact BioMedical (IBO) in Q3 2026: 2 shares worth $11. The stake represents ﹤0.01% of the portfolio and ranks #5796 among its holdings. This is a return to the name: Citigroup previously reported a position in IBO as recently as Q1 2026.

Citigroup first reported a position in IBO in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.68K in Q2 2025. 5 funds tracked by Wall St. Rank hold IBO as of Q3 2026.

Citigroup held 2 shares of Impact BioMedical worth $11 as of Q3 2026.
Impact BioMedical was a new Citigroup position in Q3 2026.
Impact BioMedical made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5796 holding.
Citigroup first reported a position in Impact BioMedical in Q2 2025 and has held it in 4 quarters since.
Citigroup's Impact BioMedical position peaked at $5.68K in Q2 2025.
5 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.